Impact of chorioamnionitis on maternal and fetal levels of proinflammatory S100A12
- PDF / 386,050 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 166 Views
ORIGINAL ARTICLE
Impact of chorioamnionitis on maternal and fetal levels of proinflammatory S100A12 Iliana Bersani 1 & Sara De Carolis 1 & Dirk Foell 2 & Toni Weinhage 2 & Cristina Garufi 3 & Maria Pia De Carolis 1 & Esther Diana Rossi 4 & Giovanna Casella 1 & Serena Antonia Rubortone 1 & Christian Paul Speer 5 Received: 6 March 2020 / Revised: 6 May 2020 / Accepted: 16 May 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS). The aim of this pilot study was to evaluate S100A12, a marker of innate immune activation, in mothers with or without HCA and in their infants. Concentrations of S100A12, interleukin 6 (IL-6), and C-reactive protein (CRP) were evaluated in maternal, cord, and neonatal blood of very preterm infants. Histologic examinations of the placenta and umbilical cords were performed. The 48 mother-neonate pairs enrolled were subdivided into two groups: HCA group (N = 15) and control group without HCA (N = 33). Maternal S100A12 levels were similar between HCA and control group. Similarly, S100A12 concentrations in cord and neonatal blood did not differ between the groups. However, high S100A12 concentrations were detected in cord and neonatal blood of two out of three neonates exposed to HCA associated with advanced funisitis. Concentrations of IL-6 and CRP were higher in maternal blood of the HCA group compared with controls (p < 0.05, p < 0.001; respectively), but no differences in cord or neonatal blood was found. Conclusion:S100A12 did neither identify mothers with HCA nor very preterm infants exposed to HCA. It is currently unknown if S100A12 may identify neonates with FIRS. What is known: • Histologic chorioamnionitis (HCA) may lead to the fetal inflammatory response syndrome (FIRS). • S100A12 represents an early, sensitive, and specific diagnostic marker of inflammatory processes.
Communicated by Daniele De Luca * Iliana Bersani [email protected]
Serena Antonia Rubortone [email protected]
Sara De Carolis [email protected] Dirk Foell [email protected]
Christian Paul Speer [email protected] 1
Department of Obstetrics, Gynaecology and Pediatrics, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy
Cristina Garufi [email protected]
2
Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany
Maria Pia De Carolis [email protected]
3
Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza University of Rome, Rome, Italy
Esther Diana Rossi [email protected]
4
Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
Giovanna Casella [email protected]
5
University Children’s Hospital, Würzburg, Germany
Toni Weinhage [email protected]
Eur J Pediatr What is new: • S100A12 did neither identify mothers with HCA nor very preterm infants expos
Data Loading...
